The immune cell infiltrate in the tumour microenvironment of phaeochromocytomas and paragangliomas.
immune cells
lymphocyte
macrophage
paraganglioma
phaeochromocytoma
tumour microenvironment
Journal
Endocrine-related cancer
ISSN: 1479-6821
Titre abrégé: Endocr Relat Cancer
Pays: England
ID NLM: 9436481
Informations de publication
Date de publication:
01 11 2022
01 11 2022
Historique:
received:
25
07
2022
accepted:
16
08
2022
pubmed:
18
8
2022
medline:
24
9
2022
entrez:
17
8
2022
Statut:
epublish
Résumé
Emerging evidence suggests the composition of the tumour microenvironment (TME) correlates with clinical outcome and that each tumour type has a unique TME including a variable population of inflammatory cells. We performed immunohistochemistry on 65 phaeochromocytoma and paraganglioma (PPGL) tumour samples with 20 normal adrenal medulla samples for comparison. The immune cells assessed were macrophages, lymphocytes and neutrophils, and we compared the proportion of infiltration of these immune cells with clinical and histopathological factors. There was a higher proportion of immune cells in tumour tissue compared to non-neoplastic adrenal medulla tissue, with a predominance of macrophages. There was a higher proportion of M2:M1 macrophages and T-helper lymphocytes in aggressive tumours compared to indolent ones. For SDHB-associated tumours, there was a higher proportion of M2 macrophage infiltration, with higher M2:M1 in aggressive SDHB PPGLs compared to indolent tumours. These data demonstrate that immune cells do infiltrate the TME of PPGLs, confirming that PPGLs are immunologically active tumours. Differences in the TME of PPGLs were observed between aggressive and indolent tumours. These differences could potentially be exploited as an aid in predicting tumour behaviour.
Identifiants
pubmed: 35975974
doi: 10.1530/ERC-22-0020
pmc: PMC9513653
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
589-598Subventions
Organisme : Cancer Research UK
ID : C16420/A18066
Pays : United Kingdom
Références
Technol Cancer Res Treat. 2013 Jun;12(3):259-67
pubmed: 23289476
Cancers (Basel). 2020 Aug 16;12(8):
pubmed: 32824391
Carcinogenesis. 2014 Aug;35(8):1780-7
pubmed: 24608042
Pathol Res Pract. 2020 Sep;216(9):153070
pubmed: 32825943
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Clin Dev Immunol. 2012;2012:948098
pubmed: 22778768
Curr Opin Endocrinol Diabetes Obes. 2021 Jun 1;28(3):283-290
pubmed: 33764930
J Neuroimmunol. 2019 Jul 15;332:233-241
pubmed: 30954278
J Cell Sci. 2012 Dec 1;125(Pt 23):5591-6
pubmed: 23420197
Clin Cancer Res. 2018 Aug 1;24(15):3717-3728
pubmed: 29666300
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Endocr Pathol. 2019 Jun;30(2):90-95
pubmed: 31001800
Endocr Relat Cancer. 2008 Dec;15(4):1069-74
pubmed: 18719091
Biochem Pharmacol. 2003 Jan 1;65(1):15-23
pubmed: 12473374
Ann Surg. 2014 Dec;260(6):1088-94
pubmed: 25389924
Cancer Cell. 2015 Apr 13;27(4):462-72
pubmed: 25858805
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Oncotarget. 2017 Feb 7;8(6):9739-9751
pubmed: 28039457
Physiol Res. 2009;58(3):319-325
pubmed: 18637714
Adv Anat Pathol. 2017 Sep;24(5):235-251
pubmed: 28777142
Front Immunol. 2019 Jul 03;10:1462
pubmed: 31333642
Clin Transl Sci. 2020 Jan;13(1):179-188
pubmed: 31550075
Endocr Relat Cancer. 2010 Dec 21;18(1):97-111
pubmed: 21051559
J Immunother Cancer. 2020 May;8(1):
pubmed: 32474412
J Endocrinol Invest. 2021 Jul;44(7):1543-1546
pubmed: 33030696
Oncotarget. 2017 Jan 31;8(31):50731-50746
pubmed: 28881599
Neuroimmunomodulation. 2007;14(1):57-64
pubmed: 17700041
Annu Rev Pharmacol Toxicol. 1995;35:417-48
pubmed: 7598501
Front Endocrinol (Lausanne). 2020 Nov 10;11:587779
pubmed: 33244312
Biomark Res. 2021 Jan 6;9(1):1
pubmed: 33407885
Front Endocrinol (Lausanne). 2020 Oct 27;11:587769
pubmed: 33193100
Cancer Cell. 2017 Feb 13;31(2):181-193
pubmed: 28162975